A5031088617- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Prostate Cancer Diagnosis and Treatment
- Renal and related cancers
- Cancer, Lipids, and Metabolism
- Epigenetics and DNA Methylation
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Testicular diseases and treatments
- Hormonal and reproductive studies
- Bone health and treatments
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Ferroptosis and cancer prognosis
- Multiple Myeloma Research and Treatments
USC Norris Comprehensive Cancer Center
2016-2025
AbbVie (United States)
2025
University of Southern California
2015-2024
Beatson West of Scotland Cancer Centre
2024
Gartnavel General Hospital
2024
Geisinger Health System
2024
Rutgers, The State University of New Jersey
2024
Rutgers New Jersey Medical School
2024
Southern California University for Professional Studies
2003-2023
Harvard University
2023
Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options.In this open-label, international, phase 3 trial, we randomly assigned 542 patients cancer recurred or progressed to receive pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1 [PD-1]) at dose of 200 mg every weeks the investigator's choice paclitaxel, docetaxel, vinflunine. The coprimary end...
Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that high levels supporting evidence.
Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence.
Genetic alterations in tumor cells often lead to the emergence of growth-stimulatory autocrine and paracrine signals, involving overexpression secreted peptide growth factors, cytokines, hormones. Increased levels these soluble proteins may be exploited for cancer diagnosis management or as points therapeutic intervention. Here, we combined use controlled vocabulary terms sequence-based algorithms predict genes encoding from among ≈12,500 sequences represented on oligonucleotide microarrays....
Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit pembrolizumab, programmed death 1 inhibitor, versus chemotherapy in UC that progressed on platinum-based chemotherapy. Here we report long-term safety and efficacy outcomes KEYNOTE-045.Adult histologically/cytologically confirmed whose disease after first-line, platinum-containing were enrolled. Patients...
We developed a preoperative nomogram for prediction of lymph node metastases in patients with clinically localized prostate cancer.The study was retrospective, nonrandomized analysis 7,014 treated radical prostatectomy at 6 institutions between 1985 and 2000. Exclusion criteria consisted androgen ablation therapy, salvage pretreatment specific antigen (PSA) greater than 50 ng/ml. Preoperative predictors PSA, clinical stage (1992 TNM) biopsy Gleason sum. These were used logistic regression...
Short-term fasting (48 hours) was shown to be effective in protecting normal cells and mice but not cancer against high dose chemotherapy, termed Differential Stress Resistance (DSR), the feasibility effect of patients undergoing chemotherapy is unknown. Here we describe 10 cases which diagnosed with a variety malignancies had voluntarily fasted prior (48-140 and/or following (5-56 chemotherapy. None these patients, who received an average 4 cycles various drugs combination fasting, reported...
Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer. We assessed the prognostic value of CTCs overall survival (OS) and disease response S0421, a phase III trial plus prednisone with or without atrasentan.CTCs were enumerated at baseline (day 0) before cycle two 21) using CellSearch. Baseline counts changes from day 0 to 21 evaluated association OS, prostate-specific...
PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers microtubule-disrupting agent, monomethyl auristatin E, to cells express Nectin-4. METHODS EV-101 is phase I dose escalation/expansion study enrolled patients with Nectin-4–expressing solid tumors (eg, metastatic urothelial carcinoma [mUC]) who progressed on ≥ 1 prior chemotherapy regimen and/or programmed death-1 receptor/programmed death...
Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials have reported variable outcomes. Vascular endothelial growth factor (VEGF) inhibitors activity against MM preclinical models. We added the anti-VEGF antibody bevacizumab to gemcitabine/cisplatin a multicenter, double-blind, placebo-controlled randomized trial patients with previously untreated, unresectable MM.Eligible had an Eastern Cooperative Oncology Group (ECOG) performance status of...
Abstract BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 administered orally at 125 mg/day on 3 weeks on, 1 week off schedule until unacceptable toxicity progression. primary endpoint the response rate. Among...
The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy 2015 for aRCC after VEGF-targeting agent. In April 2018, nivolumab ipilimumab, CTLA-4 inhibitor, intermediate- poor-risk, previously untreated aRCC. Then, 2019, combinations therapies...
The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy.In a phase III, randomized, double-blind trial, had >50% clear-cell RCC, undergone nephrectomy, and no evidence macroscopic residual or metastatic disease [independent review committee (IRC) confirmed]. intent-to-treat population included all randomized [≥pT2 and/or N+, any Fuhrman grade (FG), Eastern Cooperative Oncology Group status 0/1]....
The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared placebo after surgery in patients clear cell renal carcinoma at an increased risk recurrence. reported here, additional 6 months follow-up, was designed to assess longer-term efficacy and safety versus placebo, as well secondary exploratory endpoints.In multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, adults aged 18 years or older recurrence...
Short-term starvation prior to chemotherapy administration protects mice against toxicity. We undertook dose-escalation of fasting platinum-based determine safety and feasibility in cancer patients. 3 cohorts fasted before for 24, 48 72 h (divided as pre-chemo 24 post-chemo) recorded all calories consumed. Feasibility was defined ≥ 3/6 subjects each cohort consuming ≤ 200 kcal per during the fast period without excess Oxidative stress evaluated leukocytes using COMET assay. Insulin, glucose,...
Abstract HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor activation and has activity -mutant tumours. SUMMIT is open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib patients solid tumours harbouring oncogenic somatic (ClinicalTrials.gov: NCT01953926). The primary objective the BTC cohort, which now complete, first response rate (ORR)...
Purpose To determine the effectiveness of Alleviating Depression Among Patients With Cancer (ADAPt-C) collaborative care management for major depression or dysthymia. and Methods Study patients included 472 low-income, predominantly female Hispanic with cancer age ≥ 18 years (49%), dysthymia (5%), both (46%). were randomly assigned to intervention (n = 242) enhanced usual (EUC; n 230). Intervention had access up 12 months a clinical specialist (supervised by psychiatrist) who offered...